U.S. FDA APPROVES FIRST DRUG FOR FATTY LIVER DISEASE NASH
Mon 18 March 2024: The U.S. FDA has approved Madrigal Pharmaceuticals’ drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition and opening up a multi-billion opportunity. The company’s oral drug, called Rezdiffra, has been approved for patients who have NASH with fibrosis, or […]
Continue Reading